Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594352 | 0.90 | HDAC1 (0.51) | CTSKCTSLCTSSHDAC1HDAC2 | |
| SCHEMBL28557417 | 0.89 | MDM4 (0.45) | PTPN1MDM4TP53 | |
| SCHEMBL28557416 | 0.89 | MDM4 (0.45) | PTPN1MDM4TP53 | |
| SCHEMBL29480470 | 0.87 | CTSK (0.57) | CTSKCTSLCTSSPTPN1 | |
| SCHEMBL17446653 | 0.87 | PTPN1 (0.48) | PTPN1HDAC1HDAC2TNFMDM4 | |
| SCHEMBL30562127 | 0.85 | MDM4 (0.53) | TNFMDM4TP53 | |
| SCHEMBL23811018 | 0.85 | KMT2A (0.52) | CTSKCTSLCTSSHDAC1HDAC2 | |
| SCHEMBL17446655 | 0.84 | HDAC1 (0.50) | CTSKCTSLPTPN1HDAC1HDAC2 | |
| SCHEMBL30645058 | 0.83 | PTPN1 (0.47) | CTSKCTSLPTPN1MDM4TP53 | |
| SCHEMBL119575 | 0.83 | MDM4 (0.56) | TNFMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528834-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20220372069-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-11-24 | — | — | US | disclosed |
| EP-4036103-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | Nissan Chemical Corporation (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-114401978-A | Method for producing peptide compound | 日产化学株式会社 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528834-B2 | Method for producing peptide compound | VIP, IAPP, NPPA | CTSK 906/4885CTSL 139/4885CTSS 780/4885 |
| US-20220372069-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, NPPA, NGLY1 | CTSK 966/4885CTSL 325/4885CTSS 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.